Health insurance to exclude Novartis's Sebivo tentatively
Published: 2007-02-07 06:56:00
Updated: 2007-02-07 06:56:00
The Health Insurance Review Agency (HIRA) plans to exclude Novartis Korea's Sebivo tablet (telbivudine), a new treatment for patients with chronic hepatitis B, from the health insurance list until its price can be listed in advanced countries.
In its statement delivered to the HIRA and health ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.